Marked enhancement of the antigen-specific immune response by combining plasmid DNA-Based immunization with a Schiff base-forming drug
Marked enhancement of the antigen-specific immune response by combining plasmid DNA-Based immunization with a Schiff base-forming drug
复制标题
DOI：
10.1128/iai.70.12.6652-6657.2002
复制
发表时间：
2002-12-01
影响因子：
3.1
通讯作者：
Kiessling, R
中科院分区：
文献类型：
--
作者：
Charo, J;Sundb채ck, M;Kiessling, R
尽管基于质粒DNA（pDNA）的免疫已被证明有效，但通过这种接种途径实现的免疫应答水平通常低于传统疫苗诱导的免疫应答水平，特别是对于灵长类动物和人类。我们在这里报告了一种简单而有效的方法，通过使用两种不同的质粒编码病毒或细菌抗原，以提高基于pDNA的疫苗接种。这种方法是基于低浓度的最近描述的免疫增强，希夫碱形成药物称为妥卡雷琐，导致显着增强抗原特异性体液和细胞免疫应答的共同管理。我们的数据表明，用妥卡雷酚增强免疫应答可能为进一步开发基于pDNA的人类免疫提供有力的工具。
Although plasmid DNA (pDNA)-based immunization has proven efficacy, the level of immune responses that is achieved by this route of vaccination is often lower than that induced by traditional vaccines, especially for primates and humans. We report here a simple and potent method to enhance pDNA-based vaccination by using two different plasmids encoding viral or bacterial antigens. This method is based on coadministration of low concentrations of a recently described immunopotentiating, Schiff base-forming drug called tucaresol which has led to significant augmentation of antigen-specific humoral and cellular immune responses. Our data suggest that enhancement of the immune response with tucaresol might provide a powerful tool for the further development of pDNA-based immunization for humans.